Core Viewpoint - The company has initiated a Phase I multi-dose expansion study for LAE102, targeting obesity treatment in China, with the first subject having been dosed [1] Group 1: Study Details - The Phase I multi-dose expansion study is a randomized, double-blind, placebo-controlled trial [1] - The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 in 60 overweight/obese subjects [1] - Subjects will be randomly assigned to either the LAE102 group or the placebo group for a treatment duration of 6 months [1] Group 2: Previous Research and Future Goals - The expansion study is based on positive one-month treatment results observed in a previous MAD study [1] - The goal of the planned multi-dose expansion study is to further assess the efficacy and safety characteristics after longer-term treatment [1] - The company is committed to providing precision treatment options for patients with obesity or metabolic diseases [1]
来凯医药-B(02105.HK)：LAE102针对治疗肥胖症的I期多剂量扩展研究完成首例受试者给药